Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases

Abstract Background Extrahepatic disease progression limits clinical efficacy of Yttrium-90 (90Y) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Trifluridine and tipiracil (TAS-102) has overall survival benefit for patients with refractory mCR...

Full description

Bibliographic Details
Main Authors: Nicholas Fidelman, Chloe E. Atreya, Madeline Griffith, M. Alexandra Milloy, Julia Carnevale, Pelin Cinar, Alan P. Venook, Katherine Van Loon
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
TAS-102
Lonsurf
Trifluridine
Tipiracil
Yttrium-90
Radioembolization
Online Access:https://doi.org/10.1186/s12885-022-10401-0

Internet

https://doi.org/10.1186/s12885-022-10401-0

Similar Items